Anika Therapeutics Inc (ANIK)

46.19
NASDAQ : Health Care
Prev Close 46.45
Day Low/High 46.15 / 46.96
52 Wk Low/High 41.38 / 54.96
Avg Volume 117.70K
Exchange NASDAQ
Shares Outstanding 14.65M
Market Cap 680.71M
EPS 2.20
P/E Ratio 21.60
Div & Yield N.A. (N.A)

Latest News

Anika Announces Publication Of Phase III Data Demonstrating The Efficacy And Safety Of CINGAL® For The Treatment Of Knee Pain Associated With Osteoarthritis

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the publication of...

Biotech Movers: Anika Up on Strong Analyst Ratings

Biotech Movers: Anika Up on Strong Analyst Ratings

Anika focuses on pain management, tissue regeneration and wound healing.

Anika To Issue First-Quarter 2017 Financial Results And Business Highlights On Wednesday, May 3

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2017 financial results after the close of the market on Wednesday, May 3, 2017 and to hold a conference call...

Oversold Conditions For Anika Therapeutics (ANIK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

RSI Alert: Anika Therapeutics (ANIK) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Anika To Present At The 2017 Canaccord Genuity Musculoskeletal Conference On March 14, 2017

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Reports Fourth Quarter And Full Year 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika To Issue Fourth-Quarter 2016 Financial Results And Business Highlights On Wednesday, February 15

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2016 financial results after the close of the market on Wednesday, February 15, 2017 and to hold a conference...

Anika Wins CE Mark Approval For ORTHOVISC®-T To Relieve Pain And Restore Function Of Tendons Damaged By Chronic Injury

Anika Wins CE Mark Approval For ORTHOVISC®-T To Relieve Pain And Restore Function Of Tendons Damaged By Chronic Injury

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid "HA" technology, today announced that it received CE Mark...

Anika Therapeutics (ANIK) Shares Cross Above 200 DMA

Anika Therapeutics (ANIK) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Anika Therapeutics Inc. crossed above their 200 day moving average of $46.69, changing hands as high as $46.75 per share.

Anika To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29, 2016

Anika To Present At The Piper Jaffray 28th Annual Healthcare Conference On November 29, 2016

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its Chief Financial...

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer likes SWHC and BX, but not NAT and DBD.

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Cramer previews important earnings reports scheduled for the coming week.

Anika Reports Third Quarter 2016 Financial Results

Anika Reports Third Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics (ANIK) Shares Cross Below 200 DMA

Anika Therapeutics (ANIK) Shares Cross Below 200 DMA

In trading on Thursday, shares of Anika Therapeutics Inc. crossed below their 200 day moving average of $45.73, changing hands as low as $45.26 per share.

Anika To Issue Third-Quarter 2016 Financial Results And Business Highlights On Wednesday, October 26

Anika To Issue Third-Quarter 2016 Financial Results And Business Highlights On Wednesday, October 26

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2016 financial results after the close of the market on Wednesday, October 26, 2016 and to hold a conference...

Anika Announces Data Presentations On HYALOFAST Hyaluronic Acid-Based Scaffold At 2016 World Congress Of The International Cartilage Repair Society

Anika Announces Data Presentations On HYALOFAST Hyaluronic Acid-Based Scaffold At 2016 World Congress Of The International Cartilage Repair Society

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced four data presentations...

Anika To Participate In Upcoming Investor Conferences

Anika To Participate In Upcoming Investor Conferences

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its Chief Financial...

Anika Reports Second Quarter 2016 Financial Results

Anika Reports Second Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika To Issue Second-Quarter 2016 Financial Results And Business Highlights On Wednesday, July 27

Anika To Issue Second-Quarter 2016 Financial Results And Business Highlights On Wednesday, July 27

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2016 financial results after the close of the market on Wednesday, July 27, 2016 and to hold a conference call...

Anika Therapeutics Stock Sees Short Interest Decline 25.2%

Anika Therapeutics Stock Sees Short Interest Decline 25.2%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 392,173 share decrease in total short interest for Anika Therapeutics Inc. , to 1,165,714, a decrease of 25.17% since 06/15/2016.

Here's Whats Next for Anika Therapeutics Post-Breakout

Here's Whats Next for Anika Therapeutics Post-Breakout

The charts are showing a long-term price target of $76.

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a new lifetime high candidate

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...

3 Small Biotechs That Look Very Healthy

Peter Lynch and other market legends would love these names.

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...